Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study with Massachusetts General Hospital

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company's press release issued May 19, 2026.

The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Quantum believes this imaging approach could enhance development of MS therapies, including its investigational candidate Lucid-MS. An Investigational New Drug (IND) submission for a Phase 2 trial of Lucid-MS was submitted to the FDA in March 2026.

"Reaching the midpoint enrollment milestone in this imaging study is a significant step forward in our efforts to develop better tools for assessing demyelination in MS patients," said a company spokesperson. The ability to visualize and quantify demyelination in real time could provide critical insights into disease progression and treatment efficacy.

Multiple sclerosis affects approximately 2.8 million people worldwide, and current imaging techniques have limitations in detecting gray matter lesions and acute demyelination. The [¹⁸F]3F4AP tracer may offer a more sensitive and specific method for monitoring myelin integrity.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is focused on Lucid-MS, a patented new chemical entity that has shown ability to prevent and reverse myelin degradation in preclinical models.

The company also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets UNBUZZD™, and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum retains 100% rights to develop similar products for pharmaceutical and medical uses.

Forward-looking statements in this release involve risks and uncertainties. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.